Filtered By:
Condition: Heart Failure
Nutrition: Weight Loss

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 102 results found since Jan 2013.

Role Of Glp-1 Analogs In The Management Of Diabetes And Its Secondary Complication
Mini Rev Med Chem. 2021 Apr 21. doi: 10.2174/1389557521666210422114909. Online ahead of print.ABSTRACTThe cardiovascular complications of type 2 diabetes mellitus (T2DM) include myocardial infarction, heart failure, peripheral vascular disease and, stroke and retinopathy, nephropathy and neuropathy are microvascular complications. While the newer therapies like glitazones or even dipeptidyl-peptidase-IV (DPP-IV) inhibitors increase the risk of therapy, the Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs), were reported as suitable alternates. The GLP-1RAs reduce the major adverse cardiovascular events (MACE), have anti...
Source: Mini Reviews in Medicinal Chemistry - April 23, 2021 Category: Chemistry Authors: Ponnurengam Malliappan Sivakumar B Premkumar Prabhawathi Veluchamy Pranav Kumar Prabhakar Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Weight-Loss Surgery May Cut Risk of Heart Attack, Stroke
MONDAY, March 23, 2020 -- Weight-loss surgery is associated with a significantly lower risk of heart attack, stroke, heart failure and death, a new study reveals. The study included more than 7,400 severely obese people, average age 36, in Denmark...
Source: Drugs.com - Daily MedNews - March 23, 2020 Category: General Medicine Source Type: news

Weight-Loss Surgery Dramatically Lowers the Risk of Early Death, a New Study Finds
For decades, doctors have known that losing weight can significantly lower risk of heart disease and by extension, reduce the risk of dying from heart-related events such as stroke and heart attack. Studies have shown that both lifestyle changes including diet and exercise as well as medications and weight-loss surgery can improve heart disease risk factors such as obesity and diabetes, for example, but data supporting the benefits of any of these approaches in actually lowering rates of heart events such as heart attack and atrial fibrillation, or in reducing early deaths from heart disease, have been less robust. The dat...
Source: TIME: Health - September 2, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized diabetes Heart Disease Source Type: news

Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Authors: Madsbad S Abstract INTRODUCTION: The GLP-1 receptor agonist (GLP-1 RA) liraglutide has a half-life of approximately 13 h and is suitable for subcutaneous administration once daily. The use of liraglutide in people with type 2 diabetes has become popular because of the efficacy and durability in relation to glycemic control in combination with weight loss in most patients. Areas covered: PubMed searches were completed using the terms "GLP-1 receptor agonist", "Liraglutide", "Liraglutide and CVD", "Liraglutide and CVD risk factors". The reference list of articles subsequently identified was searched and arti...
Source: Expert Review of Cardiovascular Therapy - May 7, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Oral appliance for Obstructive Sleep Apnea: Prototyping and Optimization of the Mandibular Protrusion Device
AbstractObstructive Sleep apnea is a public health problem. This disease is associated with daytime sleepiness, increased motor vehicle accidents, heart failure and stroke. Treatment options include weight loss, positive airway pressure, pharyngeal and orthognatic surgery. However, selected patients have good response to oral appliances devices that intended to protrude and stabilize the mandible mechanically during the night in order to reduce the collapsibility of the upper airway. Selection of patients includes primary snoring, mild, moderate and positional apnea. The perfect mandibular advance device has not yet been d...
Source: Journal of Medical Systems - March 17, 2019 Category: Information Technology Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Abstract Patients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the new class of glucose-lowering medications that increase urinary glucose excretion, thus improving glycemic control, independent of insulin. The recently p...
Source: Indian Heart J - November 1, 2018 Category: Cardiology Authors: Pancholia AK Tags: Indian Heart J Source Type: research

10 Ways to Keep Your Heart Healthy
No one ever had fun visiting the cardiologist. ­Regardless of how good the doc might be, it’s always a little scary thinking about the health of something as fundamental as the heart. But there are ways to take greater control—to ensure that your own heart health is the best it can be—even if you have a family history of cardiovascular disease. Although 50% of cardiovascular-disease risk is genetic, the other 50% can be modified by how you live your life, according to Dr. Eugenia Gianos, director of Women’s Heart Health at Lenox Hill Hospital in New York City. “This means you can greatly ...
Source: TIME: Health - October 17, 2018 Category: Consumer Health News Authors: Lisa Lombardi and Jamie Ducharme Tags: Uncategorized Baby Boomer Health heart health Source Type: news

The Impact of Diet and Lifestyle on Atrial Fibrillation
AbstractPurpose of ReviewAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia in humans, affecting more than 33 million people globally. Its association with complex, resource intensive medical conditions such as stroke, heart failure and dementia have had profound impacts across existing health care structures. The global prevalence of AF has enjoyed significant growth despite significant improvement in our armamentarium for arrhythmia treatment.Recent FindingsEfforts aimed at curtailing the incidence, prevalence, or progression of AF have prompted re-evaluation of traditional frameworks for understand...
Source: Current Cardiology Reports - October 12, 2018 Category: Cardiology Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research

Hospital mortality in older patients in the Brazilian Unified Health System, Southeast region
CONCLUSIONS Although the information source has its shortcomings, the ability for discrimination of the risk adjustment model was reasonable. The variability in the risk-adjusted hospital mortality was great and comparatively higher in for-profit private hospitals. Despite the limits, the results favor the use of the risk-adjusted hospital mortality in the monitoring of the quality of hospital care provided to the older adult.RESUMO OBJETIVO Avaliar fatores associados ao óbito hospitalar em idosos internados por doenças do aparelho circulatório específicas no Sistema Único de Saúde, considerando a mortalidade hospita...
Source: Revista de Saude Publica - July 23, 2018 Category: International Medicine & Public Health Source Type: research

Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial
ConclusionCAMELLIA-TIMI 61 is investigating the safety and efficacy of lorcaserin for MACEs and conversion to diabetes in overweight or obese patients with established cardiovascular disease or multiple cardiovascular risk factors.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research